Open Cancer Trials

The following clinical trial studies are open at Kirkland Cancer Center. If you have questions, please contact Amanda Dunlap,BSN, RN at 731-541-6865 or 731-541-9561.

Type Study

Start

Date

Total Target
 

 

 

     
Breast

A011202:  Positive Sentinel Lymph Node Disease after Neoadjuvant Chemotherapy

A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) who have Positive Sentinel Lymph Node Disease after Neoadjuvant Chemotherapy.

2/07/14 275 2918
Lung

A151216:  ALCHEMIST

Adjuvant Lung Cancer Enrichment Marker identification and Sequencing Trial (ALCHEMIST) Genetic Testing for Patients with Resectable or Resected Cancer Lung Cancer

8/18/14 602 8000
Lung

E4512: Non-Small Cell Lung Cancer

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoms Kinase (ALK) Fusion Protein-Testing the Addition of the Drug Crizotinib After Surgery to Remove ALK-Positive Non-Small Cell Lung Cancer

8/18/14 10 378
Lung

A081105: Non-Small Cell Lung Cancer

A Randomized Double-Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC) Testing Whether or Not a Drug That is Known to "Target" a Certain Kind of Lung Tumor Works in Patients With That Kind of Tumor

8/18/14 35 450
Multiple Myeloma

E3A06: High-Risk Smoldering Multiple Myeloma

A Randomized Phase III Trial of Lenalidimide versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

10/05/10 158 380
Polycythemia

REVEAL: Polycythemia Vera

A Prospective, Non-Interventional Study of Disease Progression and Treatment of Patients With Polycythemia Vera in United States Academic or Community Clinical Practices

8/03/15 1876 2500
         
         
         

NONDISCRIMINATION NOTICE STATEMENT
West Tennessee Healthcare (WTH) does not exclude, deny benefits to, or otherwise discriminate against any person on the grounds of race, color, national origin, age, religion, disability, Limited English Proficiency or sex, including discrimination based on gender identity, sexual orientation, sex stereotyping or pregnancy in admission to, participation in, or receipt of the services and benefits under any of its programs and activities, whether carried out by WTH directly or through a contractor or any other entity with which WTH arranges to carry out its programs and activities.

For further information about this policy, contact Amy Garner (731) 541-9914.